Adebrelimab

Generic Name: Adebrelimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2247114-85-6

Unique Ingredient Identifier: 1XBY50W1OX

Background: Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication: 用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Phase 2

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Adebrelimab
Drug: Lenvatinib
Procedure: Hepatic Arterial Infusion Chemotherapy

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: Harbin Medical University

Target Recruit Count: 30

Registration Number: NCT06389500

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase 1

Not yet recruiting

Conditions: Advanced KRAS G12D Mutant Solid Tumors

Interventions: Drug: HRS-4642
Drug: SHR-A1921
Drug: Adebrelimab
Drug: Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection

First Posted Date: 2024-04-26

Last Posted Date: 2024-04-26

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 70

Registration Number: NCT06385678

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: RC48
Drug: Adebrelimab
Drug: Apatinib
Drug: S-1

First Posted Date: 2024-04-26

Last Posted Date: 2024-05-13

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 32

Registration Number: NCT06385873

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Phase 2

Not yet recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Adebrelimab

First Posted Date: 2024-04-19

Last Posted Date: 2024-04-19

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06375642

Locations: 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Phase 1

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: SHR-8068
Drug: Adebrelimab
Drug: BP102

First Posted Date: 2024-04-18

Last Posted Date: 2024-04-18

Lead Sponsor: West China Hospital

Target Recruit Count: 36

Registration Number: NCT06373133

Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2

Not yet recruiting

Conditions: Nasopharyngeal Cancer
Nasopharyngeal Carcinoma

Interventions: Drug: Adebrelimab

First Posted Date: 2024-04-05

Last Posted Date: 2024-04-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT06349889

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Drug: Adebrelimab
Drug: Apatinib
Drug: Tegafur

First Posted Date: 2024-04-01

Last Posted Date: 2024-04-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 32

Registration Number: NCT06339619

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: HS-20089
Drug: Adebrelimab
Drug: Bevacizumab
Drug: Cisplatin / carboplatin

First Posted Date: 2024-03-29

Last Posted Date: 2024-07-18

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 1048

Registration Number: NCT06336707

Locations: 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Shanghai, Shanghai, China

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: HS-20093
Drug: Adebrelimab
Drug: Cetuximab
Drug: Enzalutamide
Drug: Cisplatin/ Carboplatin

First Posted Date: 2024-03-27

Last Posted Date: 2024-07-18

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 610

Registration Number: NCT06332170

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

Phase 2

Not yet recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: adebrelimab
Drug: famitinib
Drug: chemotherapy

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-12

Lead Sponsor: Harbin Medical University

Target Recruit Count: 40

Registration Number: NCT06306560

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy